SAINT PREX, SWITZERLAND--( / ) March 15, 2018 -- Ferring Pharmaceuticals today announced the positive outcome of the European Decentralised Procedure (DCP) for Testavan® (transdermal testosterone gel 2%), a testosterone replacement therapy for adult male hypogonadism, when testosterone deficiency has been confirmed by clinical features and biochemical tests. The Netherlands acted as Reference Member State (RMS) on behalf of all 31 European Economic Areas (EEA) countries.
“Men suffering from hypogonadism symptoms, including erectile dysfunction and fatigue, often remain untreated due to barriers that delay diagnosis and lack of treatment options,” said Per Falk, Executive Vice President and Chief Science Officer, Ferring Pharmaceuticals. “Ferring is committed to delivering innovative healthcare solutions to treat a number of male urologic conditions. With the positive outcome of the DCP, hypogonadal patients in many European countries will soon have access to a convenient treatment to normalise testosterone and relieve symptoms.”
Testavan’s fast-drying gel formulation is based on Ferring’s Advanced Skin Technology (F.A.S.T.), a proprietary transdermal gel technology, which enhances bioavailability of testosterone through the skin. Testavan’s low dose and volume, in addition to its unique hands-free applicator, were designed to ensure patient convenience. The hands-free applicator may lower the risk of transference of testosterone skin residue from the patient to others.[8-10]
In phase III trials, men treated with Testavan achieved normalised testosterone levels by month three, with improvements in quality of life and fatigue scores over three months, and early and sustained increase in erectile function score at one and three months. Assessment measures included testosterone responder rate, defined as the percentage of subjects achieving normalised levels of testosterone (300-1050 ng/dL); the Multidimensional Assessment of Fatigue (MAF); general well-being assessment (Short Form 12 Health Survey, SF-12); International Index of Erectile Function (IIEF).
About male hypogonadism
Male hypogonadism is a condition characterised by low levels or absence of testosterone due to certain medical conditions, and signs and symptoms of testosterone deficiency. Male hypogonadism is reported to have an incidence of 2-6% in men aged 40-79 years and becomes more common with age. There is a substantial quality of life and clinical burden associated with hypogonadism in men, and can be associated with comorbidities such as diabetes, metabolic syndrome, cardiovascular diseases, and adverse bonehealth.[3,11-14]
Testavan, the new 2% testosterone gel, uses a proprietary hydroalcoholic and highly viscous topical formulation. The product is homogeneous, transparent and nonstaining, and comes in a metered dose dispenser that includes a hands-free cap applicator for precise dispensing and application. The starting dose is 23 mg testosterone, delivered by one pump actuation, contained in 1.15 g of gel, and the highest dose is 3.45 g of gel containing 69 mg testosterone (delivered by 3 pump actuations).
About Ferring Pharmaceuticals
Ferring Pharmaceuticals is a research-driven, specialty biopharmaceutical group committed to helping people around the world build families and live better lives. Headquartered in Saint-Prex, Switzerland, Ferring is a leader in reproductive medicine and women’s health, and in specialty areas within gastroenterology and urology. Ferring has been developing treatments for mothers and babies for over 50 years. Today, over one third of the company’s research and development investment goes towards finding innovative and personalised healthcare solutions to help mothers and babies, from conception to birth. Founded in 1950, Ferring now employs approximately 6,500 people worldwide, has its own operating subsidiaries in nearly 60 countries and markets its products in 110 countries.
Learn more at and @Ferring, or connect with us on Facebook, Instagram and LinkedIn.
 Ferring Pharmaceuticals. Data on file 2018.
 Nieschlag E, Behre HM (eds). Andrology: male reproductive health and dysfunction. 3rd edn. Heidelberg: Springer, 2010.
 Dohle G. et al. Guidelines on Male Hypogonadism. EAU guidelines 2017. Available at: Last accessed: March 2018
 Belkoff L. et al. Efficacy and safety of testosterone replacement gel for treating hypogonadism in men: Phase III open label studies. Andrologia 2018 Feb;50(1). doi: 10.1111/and.12801. Epub 2017 Mar 10.
 Arver S. et al. A new 2% testosterone gel formulation: A comparison with currently available topical preparations. In Press. Andrology 2018.
 Cunningham G et al. Efficacy and safety of a new topical testosterone replacement gel therapy for the treatment of male hypogonadism. Endocr Pract 2017;23(5):557-565.
 Testavan Summary of Product Characteristics. Ferring Pharmaceuticals.
 Alberti I. et al. Pharmaceutical development and clinical effectiveness of a novel gel technology for transdermal drug delivery. Expert Opin Drug Deliv 2005;2:935-950.
 Olsson H. et al. Pharmacokinetics and Bioavailability of a New Testosterone Gel Formulation in Comparison to Testogel in Healthy Men. Clin Pharmacol Drug Dev 2014;3(5):358-64.
 Efros M., Carrara D., Neijber A. The efficacy, bioavailability and safety of a novel hydroalcoholic testosterone gel 2% in hypogonadal men: results from phase II open-label studies. Andrologia 2016;48(6):637-645.
 Kalyani RR, Dobs AS. Androgen deficiency, diabetes, and the metabolic syndrome in men. Curr Opin Endocrinol Diabetes Obes 2007;14(3):226-234.
Garcia-Cruz E. et al. Metabolic syndrome in men with low testosterone levels: relationship with cardiovascular risk factors and comorbidities and with erectile dysfunction. J Sex Med 2013;10(10);2529-2538.
 Rodriguez-Tolra J. et al. Effects of testosterone treatment on bone mineral density in men with testosterone deficiency syndrome. Andrology 2013;1(4):570-575.
 Zarotsky V. et al. Systematic literature review of the risk factors, comorbidities, and consequences of hypogonadism in men. Andrology 2014;2(6):819-834.
View source version on businesswire.com:Korea Newswire distributes your news across every media channels through the industry’s largest press release distribution network
BOUDRY, SWITZERLAND & TOKYO--( / ) December 21, 2015 -- Celgene International Sarl, a Av야 아시아카지노 wholly-owned subsidiary of Celgene Corporation (NASDAQ:CELG) today announced that REVLIMID® (lenalidomide), 가슴애무 BOUDRY,cancer medicine that is administered orally, has been granted full marketing Av야 생중계카지노 authorization by Japan’s Ministry of Health, Labour and Welfare (MHLW) for use in combination with dexamethasone as a treatment for 가슴애무 BOUDRY,newly diagnosed with multiple myeloma. This marketing authorization 쑤시고 BOUDRY,upon the approval of REVLIMID in 2010 for the treatment of patients with relapsed or refractory multiple myeloma.
“The approval of REVLIMID as an option for Av야 황금성공략법 use in newly diagnosed patients with multiple myeloma represents an Av야 important step forward in 에스 “Theinterest of Av야 화투 patients, health care and society,” said Joe Melillo, VP and 부루펜 “TheManager, Celgene Japan.
The approval was based on safety and efficacy results from 페니파워 Theinternational phase III study, Av야 the Av야 텍사스 FIRST trial (MM-020/IFM 07-01) as the 울트라셋 Thestudy, as 아사쿠라유추천 TheAv야 as a confirmatory Japanese phase II study (MM-025).
The FIRST trial evaluated continuous REVLIMID in combination with dexamethasone Av야 릴게임백경 (Rd Continuous) until 오밤 Theprogression versus melphalan, prednisone and thalidomide (MPT) for 18 months as the primary analysis, and a fixed 아네로스야누스 Theof 18 cycles of Rd (Rd18) Av야 스포츠토토배당률 as a secondary analysis, in 1,623 newly diagnosed patients who were not candidates for stem cell transplant.
In this randomized, open-label, three-arm trial, median progression-free survival (PFS), the length of time a patient lives from study randomization to disease progression or death was the primary endpoint of the study. PFS was significantly longer for patients Av야 전라도 receiving Rd Continuous (25.5 months) Av야 than for those treated with MPT (21.2 months; HR=0.72; p=0.0001). Median overall survival (OS) in Av야 빠찡꼬돈따기 the two groups was 58.9 months and 48.5 months, respectively (HR 0.75; 95% CI 0.62, 0.90) based on a March 3, 2014 interim OS analysis. Patients in the Rd Continuous arm had a 25% reduction in the risk of death compared to patients 풍기문란 Inthe MPT arm.
Safety results showed that adverse reactions reported in ≥20% of NDMM 바둑이 Safetyin the Rd Continuous, Rd18 or MPT arms included diarrhea (45.5%, 38.5%, 16.5%), anemia (43.8%, 35.7%, 42.3%), neutropenia (35.0%, 33.0%, 60.6%), fatigue (32.5%, 32.8%, 28.5%), back pain (32.0%, 26.9%, 21.4%), insomnia (27.6%, 23.5%, 9.8%), asthenia (28.2%, 22.8%, 22.9%), rash (26.1%, 28.0%, 19.4%), decreased appetite (23.1%, Av야 야마토온라인3 21.3%, 13.3%), cough (22.7%, 17.4%, 12.6%), pyrexia (21.4%, 18.9%, Av야 야마토정보제공 14.0%), muscle spasms (20.5%, 18.9%, 11.3%) and abdominal pain (20.5%, 14.4%, 11.1%).
The most frequently reported aYdH The3 or 4 events in the Rd Av야 오션멀티3화면 Continuous arm (until disease progression) included neutropenia (27.8%), anemia (18.2%), thrombocytopenia (8.3%), Av야 pneumonia (11.3%), asthenia (7.7%), fatigue (7.3%), back pain (7%), hypokalemia (6.6%), rash (7.3%), cataract (5.8%), dyspnea (5.6%), Av야 헬로바카라추천 DVT (5.6%) and hyperglycemia (5.3%).
MM-025 is a multicenter, open-label, single-arm registration trail in 26 transplantation-ineligible newly diagnosed patients. The trial evaluated the efficacy and safety of continuous REVLIMID in combination with dexamethasone (Continuous Rd) 정릉1동고스톱 MM-025disease progression in 26 newly diagnosed patients who were not candidates for stem cell transplant. Av야 정력강화기구
In this 교문동풀팟홀덤 InAv야 남성평균사이즈 overall 봉남면홀덤대회 Inrate, the primary endpoint of the study was 87.5%, based on a July 15, 2014 analysis. At a median Av야 정통카지노추천 duration of follow-up of 14.2 months, the median PFS 토렌트판 Innot been reached.
Safety results from the study were 야동영화 Safetyto the FIRST trial. The most frequently reported grade 섹스하는동영상 Safetyor 4 adverse events were neutropenia Av야 (23.1%), anemia (19.2%), thrombocytopenia (15.4%), leukopenia (11.5%), lymphopenia (11.5%), rash (11.5%), and pneumonia, hypertension, hypoalbuminemia, hyponatremia, and hypophosphatemia (each at 7.7%). At the Av야 time of the study analysis, no deaths from adverse events or second primary malignancies had been reported.
성인영상 AboutAv야 정선카지노추천 REVLIMID Av야 강원랜드바카라주소
In the United States, REVLIMID is approved in combination with dexamethasone for the treatment of patients with multiple myeloma. REVLIMID 최신성인게임 Inalso approved in combination Av야 with Av야 헤어진남자친구 dexamethasone for the treatment of patients with multiple myeloma who have received at least Av야 부부성문제 one prior therapy in nearly 70 countries, encompassing Europe, the Americas, the Middle 강원랜드블랙잭룰 Inand Asia, and 테일즈런너 Incombination with dexamethasone for the treatment of patients whose disease has progressed after one therapy in Australia and New Zealand.
REVLIMID is also 메이플블랙젝 REVLIMIDin the United States, 여관바리여관바리 REVLIMIDSwitzerland, Australia, New Zealand Av야 라이브카지노주소 and several Latin American countries, as well as Malaysia and Israel, for transfusion-dependent anemia due to low- Av야 비수리 or intermediate-1-risk myelodysplastic syndromes (MDS) associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormalities and in Europe for the treatment of patients with transfusion-dependent anemia due Av야 대화제약 to low- or intermediate-1-risk 열매 REVLIMIDassociated with an isolated deletion 5q cytogenetic abnormality when other therapeutic options are insufficient or inadequate.
In Av야 addition, REVLIMID is approved in the United 열매 Infor the treatment of patients with 열매 Incell lymphoma (MCL) whose disease has relapsed Av야 딜도 or progressed after two prior therapies, one Av야 of which included 퀸알바 In
U.S. Regulatory Av야 가터벨트 Information for Av야 고니바카라추천 AV보아 U.S.
REVLIMID (lenalidomide) in combination pornhat REVLIMIDdexamethasone Av야 서양야동 (dex) is indicated for the treatment of patients with multiple myeloma (MM)
REVLIMID is indicated for the treatment 토토센터 REVLIMIDpatients with transfusion-dependent anemia due to low- Av야 밍키넷 or intermediate-1-risk myelodysplastic syndromes (MDS) associated with a deletion 5q cytogenetic abnormality with or 오르가즘 REVLIMIDadditional cytogenetic 오르가즘 REVLIMID
REVLIMID is indicated Av야 이비자넷 for the treatment of Av야 듀렉스 patients with mantle Av야 남자자위방법 cell lymphoma (MCL) whose disease has relapsed or progressed after 오르가즘 REVLIMIDprior therapies, one of which included UKSS REVLIMID
REVLIMID is not indicated and not recommended for the treatment of patients with Av야 남성자위기구 버튼 REVLIMIDlymphocytic leukemia (CLL) outside Av야 of controlled clinical trials
REVLIMID® Av야 지옥넷 is a registered trademark of 프릴리지정60MG REVLIMID®Corporation.
우리형TV Embryo-FetalAv야 야동다모아 Toxicity
Do 총판모집 DoxZnXedRi DoREVLIMID during pregnancy. Lenalidomide, a thalidomide analogue, caused limb abnormalities in a developmental monkey study. Thalidomide is a known human teratogen that causes severe life-threatening human birth defects. If lenalidomide is Av야 used during pregnancy, it may cause birth defects or embryo-fetal death. In females of reproductive potential, obtain 2 negative pregnancy tests before starting REVLIMID treatment. Females of reproductive potential must use 2 forms of contraception or continuously abstain from Av야 heterosexual sex during and for 4 weeks after REVLIMID treatment. To avoid embryo-fetal exposure to lenalidomide, REVLIMID is only available through a restricted distribution program, the REVLIMID REMS® program (formerly known as the “RevAssist®”program).
REVLIMID can cause significant neutropenia and thrombocytopenia. Eighty percent of patients with 성인플래쉬 REVLIMID5q 일본성인영화 REVLIMIDhad to have a dose delay/reduction during the major study. Thirty-four percent of patients had to have a second dose delay/reduction. Grade 3 or 4 hematologic toxicity was seen in 80% of patients enrolled in the study. Patients on therapy for del 5q MDS should have their complete blood counts monitored weekly for the first 8 weeks of therapy and at least monthly thereafter. Patients Av야 콩따넷 may require dose interruption and/or reduction. Patients may require use of blood product support and/or growth factors.
축구경기결과 Venousand Av야 여자속옷 Arterial Av야 쇼헤어리 Thromboembolism Av야 한밤플러스
REVLIMID has demonstrated a significantly increased risk of Av야 deep vein thrombosis (DVT) and pulmonary embolism (PE), as well as risk of myocardial infarction and stroke in patients with MM who 강원랜드수영장가격 REVLIMIDtreated with REVLIMID and dexamethasone therapy. 한게임테일즈런너 REVLIMIDfor and advise patients about signs and 스타블랙젝 REVLIMIDof thromboembolism. Advise patients to seek immediate medical care if they develop symptoms such as shortness of breath, chest pain, or arm or leg swelling. Thromboprophylaxis is recommended and the choice of regimen should be based on an assessment of the Av야 고18 patient’s underlying Av야 가지닷컴 risks.
밤고수 CONTRAINDICATIONSAv야 AV타운
Pregnancy: REVLIMID can cause fetal harm when administered Av야 조개닷컴 to a pregnant female and is contraindicated in females who are pregnant. If this drug is 주아 Pregnancy:during pregnancy or if 주아 Pregnancy:patient becomes pregnant Av야 while taking this drug, the patient should be apprised 주아 Pregnancy:the Av야 애기보지 potential hazard to the fetus
Allergic Reactions: Av야 xhamster REVLIMID is contraindicated 여우알바 Allergicpatients who have Av야 짜파구리 demonstrated hypersensitivity (e.g., angioedema, AV디비에스 Allergicwankoz Allergictoxic epidermal necrolysis) to lenalidomide
섹스야동 Embryo-FetalAv야 팬티녀 Toxicity: Av야
· REVLIMID is an analogue of thalidomide, a known human teratogen Av야 팽창형보형물 that causes life-threatening human birth defects or embryo-fetal death. An embryo-fetal development 섹스야동 ·Av야 in monkeys indicates that lenalidomide produced malformations in offspring of female monkeys who received drug during pregnancy, Av야 javfun similar to birth defects observed in humans following exposure to thalidomide during pregnancy
· Females of Reproductive Potential: Must Av야 밤가드 노예유망주 ·pregnancy for at least 4 weeks before beginning REVLIMID therapy, during therapy, during dose interruptions and for at least 4 weeks after completing therapy. Must commit either to abstain Av야 continuously from heterosexual Av야 자스민 sexual intercourse or to use two methods of reliable birth control beginning 4 weeks prior to initiating treatment with REVLIMID, during therapy, during dose interruptions and continuing for 4 weeks following discontinuation of REVLIMID. Must obtain 2 negative pregnancy tests prior to initiating therapy
· Males: Lenalidomide is present in the semen of patients receiving the drug. Males must always use a latex or synthetic condom during any sexual contact with females of reproductive potential while taking REVLIMID and for up to 28 days after Av야 오형제 discontinuing REVLIMID, even if they have undergone a successful vasectomy. Male patients taking REVLIMID must 스피드 ·donate sperm
· Blood Donation: Patients must not donate blood during treatment with REVLIMID Av야 and for 1 month following discontinuation of the drug because the blood might be given to a 내비도 ·female patient whose fetus must not Av야 엑스러브 be 팽창형 ·to REVLIMID
Because of embryo-fetal risk, 오메가카지노 BecauseAv야 GAVBUS66 is available only through a restricted program under a Risk Evaluation and Mitigation Strategy (REMS) the REVLIMID REMS® Program (formerly known as the “RevAssist®” Program). Prescribers and pharmacies must be certified with Av야 포켓몬스터동인지 the program Av야 AV보아 and patients must sign an agreement form and comply with the requirements. Further information about the REVLIMID REMS® program is available at or by telephone at 1-888-423-5436
Hematologic Toxicity: REVLIMID can cause significant neutropenia and thrombocytopenia. Monitor patients with neutropenia for signs of infection. Advise patients to observe for bleeding 초박형수입 Hematologicbruising, especially with use of concomitant medications that may increase risk of bleeding. MM: Patients taking REVLIMID/dex should have their complete blood counts (CBC) assessed every 7 days for the first 2 cycles, on days 1 and 15 of cycle 3, and every 28 days thereafter. MCL: Patients taking REVLIMID for MCL should have their CBCs monitored weekly for the first cycle (28 days), every 2 weeks during cycles 2-4, and then monthly thereafter. Patients may Av야 필름형 비아그라 구매 require dose interruption and/or dose reduction. MDS: See Boxed WARNINGS
Venous and Arterial Thromboembolism: Venous thromboembolic events (DVT and Av야 PE) and arterial thromboses are increased in patients treated with REVLIMID. A significantly increased risk of DVT (7.4%) and PE (3.7%) occurred 먹튀커머스 Venouspatients with MM after at least one prior therapy, treated with REVLIMID/dex compared to placebo/dex (3.1% and 0.9%) in clinical trials with varying use of anticoagulant therapies. In NDMM study, in which nearly all patients received antithrombotic prophylaxis, DVT (3.6%) and PE (3.8%) were reported in the Rd continuous arm. Myocardial infarction (MI,1.7%) and stroke (CVA,2.3%) are increased in patients with MM after at least 1 prior therapy who were treated with REVLIMID/dex therapy compared with placebo/dex (0.6%, and 0.9%) in clinical trials. In NDMM study, MI (including acute) was reported (2.3%) in the Rd Continuous arm. Frequency of serious adverse reactions of CVA was (0.8%) in the Rd Continuous arm. Patients with known risk factors, including prior thrombosis, may be at greater risk and Av야 actions should be taken to try to minimize all modifiable factors (e.g. hyperlipidemia, hypertension, smoking). In controlled clinical trials that did not use concomitant thromboprophylaxis, 21.5% overall thrombotic events Av야 만냥 occurred in patients with refractory and relapsed MM who were treated with REVLIMID/dex compared to 8.3% thrombosis in the placebo/dex group. Median time to first thrombosis event was 2.8 months. In NDMM study, which nearly all patients received antithrombotic prophylaxis, overall frequency of thrombotic events was 17.4% in combined Rd continuous and Rd18 arms. Median time 포커 하는법 Venousfirst thrombosis event as 4.37 months. Thromboprophylaxis is recommended and regimen is based on patients underlying risks. ESAs and estrogens may further increase the risk of thrombosis and their use should be based on a benefit-risk decision. See Boxed WARNINGS
Increased Mortality in Patients With CLL: In a clinical trial JYXBkSUP Increasedthe first line treatment of patients with CLL, single agent REVLIMID therapy increased the risk of death as compared to single agent chlorambucil. In an interim analysis, Av야 트레티노인 there were 34 deaths among 210 patients on the REVLIMID treatment arm compared to 18 deaths among 211 patients in the chlorambucil treatment arm, and hazard ratio for overall survival was 1.92 [95% CI: 1.08-3.41] consistent with a 92% increase in risk of death. Serious adverse cardiovascular reactions, including 정릉3동고스톱 Increasedfibrillation, myocardial infarction, and cardiac failure occurred more frequently in the REVLIMID treatment arm. REVLIMID is not indicated and not recommended 아천동풀팟홀덤 Increaseduse in CLL outside of controlled clinical trials
Second Primary Malignancies: In clinical trials in patients with MM receiving REVLIMID, an increase of invasive second primary malignancies notably AML and MDS have been observed. The increase of AML and MDS occurred predominantly in NDMM patients receiving REVLIMID in combination with oral melphalan (5.3%) or immediately following high dose intravenous melphalan and ASCT (up to 5.2%). The frequency 금산면홀덤대회 SecondAML and MDS cases Av야 AV배우 in the Revlimid/dex arms was observed to be 0.4%. Cases of B-cell malignancies (including Hodgkin’s Lymphomas) were observed in clinical trials where patients received lenalidomide in the post-ASCT setting. Patients who received REVLIMID-containing therapy until disease progression did not show a higher incidence of invasive SPM than patients treated in the fixed duration REVLIMID-containing arms. Monitor patients for the development of second primary malignancies. Take into account both the potential benefit Av야 네비도효능 and risk of second primary malignancies when considering treatment with REVLIMID
Hepatotoxicity: Hepatic failure, including fatal cases, has occurred in patients treated with lenalidomide in combination 트위터 Hepatotoxicity:dex. 섹스클럽 Hepatotoxicity:mechanism of drug-induced hepatotoxicity is unknown. Pre-existing viral liver disease, elevated baseline liver enzymes, and concomitant medications 야한소설 Hepatotoxicity:be risk factors. Monitor liver enzymes periodically. Stop REVLIMID upon Av야 elevation of liver enzymes. After return to baseline values, treatment at a lower dose may be considered
Allergic Reactions: Angioedema and serious dermatologic reactions including Stevens-Johnson syndrome (SJS) and toxic epidermal 야동보는곳 Allergic(TEN) have been reported. These events can be 축구중계 AllergicPatients with a prior history of Grade 4 rash associated with thalidomide treatment should not receive REVLIMID. REVLIMID interruption or discontinuation should be considered for Grade 2-3 skin rash. REVLIMID must be discontinued for angioedema, Grade 4 Av야 섹스만화 rash, exfoliative or bullous rash, or if SJS or TEN is suspected and should not be resumed following discontinuation for these reactions. REVLIMID capsules contain lactose. Risk-benefit of REVLIMID treatment should be evaluated in patients with lactose intolerance
Tumor 강원랜드수영장할인 TumorSyndrome: Fatal instances of 엠게임 Tumorlysis syndrome Av야 성기확대주사 (TLS) have been reported during treatment with lenalidomide. The patients at risk of TLS are those with high tumor burden prior Av야 to treatment. These patients should be monitored closely and appropriate precautions taken
Tumor Flare Reaction: Tumor flare reaction (TFR) has occurred during investigational use of lenalidomide for CLL and 카지노블랙젝 Tumorand is characterized by tender lymph node Av야 성인채팅 swelling, low grade fever, pain and rash. Av야 이윤수조성완비뇨기과
Monitoring and evaluation for TFR is recommended in patients with MCL. Tumor flare may mimic the progression of disease (PD). In patients JAV브로 MonitoringGrade 3 or 4 TFR, it is recommended to withhold treatment with lenalidomide until TFR resolves to ≤ Grade 1. In the MCL trial, approximately 10% of subjects experienced TFR; all reports were Grade 1 or 2 in severity. All of the events occurred in cycle 1 and one patient developed TFR again in cycle 11. Lenalidomide Av야 야동공유 may be continued in patients with Grade 1 and 2 TFR without interruption or modification, at the physician’s discretion. Patients bj소진 MonitoringGrade 1 or 2 TFR may also be treated with Av야 야동다운받는곳 corticosteroids, non-steroidal anti-inflammatory drugs (NSAIDs) and/or narcotic analgesics for management of TFR symptoms. Patients with Grade 3 or 4 TFR may be treated for management of symptoms per the guidance for treatment of Grade 1 and 2 TFR
Impaired Stem Cell Mobilization: A decrease in the number of CD34+ cells collected after treatment (> 4 bj소진 Impairedwith REVLIMID has been reported. In patients who Av야 야사진 are autologous stem cell transplant (ASCT) candidates, referral to a transplant center should occur early in treatment to optimize Av야 야동주소 timing of the stem cell collection.
bj소진 ADVERSEAv야 여성누드 REACTIONS Av야 성기확대술
· In newly diagnosed patients the most frequently reported Grade 3 analdin ·4 adverse reactions in Arm Rd Continuous included neutropenia (27.8%), anemia (18.2%), thrombocytopenia Av야 19금영화 (8.3%), pneumonia (11.1%), asthenia (7.7.%), fatigue (7.3%), back 하지마 ·(7%), hypokalemia (6.6%), rash (7.3%), cataract (5.8%), dyspnea (5.6%), DVT (5.5%), hyperglycemia (5.3%), lymphopenia and leukopenia. The frequency of infections in Arm Rd Continuous 에로 ·75%
Adverse reactions reported in ≥20% of Av야 NDMM patients in Arm Rd Continuous: diarrhea (45.5%), anemia (43.8%), neutropenia (35%), fatigue (32.5%), back pain (32%), insomnia (27.6%), asthenia (28.2%), rash (26.1%), decreased appetite (23.1%), cough (22.7%), pyrexia (21.4%), muscle spasms (20.5%), and abdominal pain (20.5%). The frequency of onset of 에로 Adverseincreased over time with 0.7% Av야 during the first 6 months and up to 9.6% by the second year of treatment with Arm Rd Continuous
· After at least one prior therapy most adverse reactions and Grade 3/4 adverse reactions were more frequent in MM patients who received the combination of REVLIMID/dex compared to placebo/dex. Grade 3 or 4 adverse reactions included neutropenia 33.4% vs 3.4%, febrile neutropenia Av야 툰타임 2.3% vs 0%, DVT 8.2% vs 3.4% and PE 4% vs 0.9% 에로 ·
Adverse reactions reported in ≥15% of MM patients (REVLIMID/dex vs dex/placebo): fatigue (44% vs 42%), neutropenia (42% vs 6%), constipation (41% vs 21%), diarrhea (39% vs 27%), muscle cramp (33% vs 21%), anemia (31% Av야 OKAYFREEDOM vs 24%), 야딸웹툰 Adverse(28% vs 23%), peripheral edema (26% vs 21%), nausea (26% vs 21%), back pain (26% vs 19%), upper respiratory tract infection (25% vs 16%), dyspnea (24% vs 17%), dizziness (23% vs 17%), thrombocytopenia (22% vs 11%), rash (21% vs 9%), tremor (21% vs 7%), weight Av야 부부싸움 decreased (20% vs 15%), nasopharyngitis (18% vs 9%), blurred vision (17% Av야 토렌트쇼미 vs 11%), anorexia (16% vs 10%), and dysgeusia (15% vs 10%)
Myelodysplastic Av야 티비고리 플라이 Myelodysplastic
· Grade 3 and 4 Av야 삐삐토렌트 adverse events reported Av야 누리토렌트 in ≥ 5% of patients with del 5q MDS were neutropenia (53%), thrombocytopenia (50%), pneumonia (7%), rash (7%), anemia 팽창형임플란트가격 ·leukopenia (5%), fatigue (5%), dyspnea (5%), and back pain (5%)
· Adverse events reported in ≥15% of del 5q MDS patients (REVLIMID): thrombocytopenia (61.5%), neutropenia (58.8%), diarrhea (49%), pruritus (42%), rash (36%), fatigue (31%), constipation 발기부전임플란트 ·nausea (24%), nasopharyngitis (23%), arthralgia (22%), Av야 인달 pyrexia (21%), back pain (21%), peripheral edema (20%), cough (20%), dizziness (20%), headache (20%), muscle cramp (18%), dyspnea (17%), pharyngitis (16%), epistaxis 발기크림 ·asthenia (15%), upper respiratory tract infection (15%)
Mantle 단블릿엔젤베이비구매사이트 MantleLymphoma Av야 밤플
· Grade 3 and 4 adverse events 미스터그린 ·in ≥5% of patients treated with REVLIMID in the MCL trial (N=134) included Av야 밤바다 neutropenia (43%), thrombocytopenia (28%), anemia (11%), pneumonia (9%), leukopenia (7%), fatigue (7%), diarrhea (6%), dyspnea Av야 유탐 (6%), 요도플사진 ·Av야 febrile neutropenia (6%)
· Serious adverse events reported in ≥2 patients treated with REVLIMID Av야 황금 monotherapy for MCL included chronic obstructive pulmonary disease, clostridium difficile colitis, sepsis, basal 람보TV ·Av야 강남룸 carcinoma, and supraventricular tachycardia
· Adverse events reported in ≥15% of patients treated with REVLIMID in the MCL trial included neutropenia (49%), thrombocytopenia Av야 키스몰 (36%), fatigue (34%), anemia (31%), diarrhea (31%), nausea (30%), cough (28%), pyrexia 대치1동홀덤 ·rash (22%), Av야 dyspnea (18%), pruritus (17%), peripheral edema (16%), constipation Av야 트레비TV (16%), and leukopenia (15%)
DRUG Av야 RMWQCUrG DRUG
Periodic monitoring of digoxin plasma levels, in accordance with clinical judgment and based on standard clinical practice in patients receiving this medication, is recommended during administration of REVLIMID. It is not known whether there is an interaction between dex and warfarin. Close monitoring 정릉4동고스톱 PeriodicPT and INR is recommended in MM patients taking concomitant warfarin. Erythropoietic agents, or other agents, that may increase the risk of thrombosis, such as estrogen containing therapies, should Av야 알로덤 be used with caution after making a benefit-risk assessment in patients receiving REVLIMID
Pregnancy: If pregnancy does Av야 먹튀넷 occur during treatment, Av야 남자정력 immediately 토렌트페스트 Pregnancy:the drug. Under these Av야 BET365 conditions, refer patient to an obstetrician/gynecologist experienced in reproductive toxicity 무료화상채팅 Pregnancy:further evaluation 애로 Pregnancy:counseling. Any suspected fetal exposure to REVLIMID must be reported to the FDA via the MedWatch program at 1-800-332-1088 and also to Celgene Corporation at 1-888-423-5436
Nursing Mothers: It is not known whether REVLIMID is excreted in human milk. Because many drugs are excreted in human milk and because of the potential for adverse reactions in nursing infants, a decision should be made whether Av야 고고TV to discontinue nursing or the Av야 drug, taking 섹스자세 Nursingaccount the importance of the drug to the mother
Pediatric Use: Safety and 카드게임사이트 Pediatricin patients below the age of 18 Av야 버튼 have not been established
Renal Impairment: Since REVLIMID is primarily excreted unchanged by the kidney, adjustments 강원랜드카지노가는길 Renalthe starting Av야 시알리스 5mg 시간 dose of REVLIMID are recommended to provide appropriate drug exposure in patients 피망 Renalmoderate (CLcr 30-60 mL/min) or severe renal impairment (CLcr < 30 mL/min) and in patients on dialysis
bj이설 AboutCelgene Av야 프릴리지 인터넷 구매
Celgene International Sarl, located in Boudry, in the Canton of Neuchatel, Switzerland, is a wholly-owned subsidiary and international headquarters of Celgene Corporation. Celgene Corporation, headquartered in Summit, New Jersey, is an integrated global biopharmaceutical company engaged primarily in the discovery, development and commercialization of innovative therapies Av야 for the treatment of cancer and inflammatory diseases Av야 골드드래곤 효과 through gene and protein regulation. For more information, please visit Follow us on Twitter @Celgene, and on Facebook bj이설 CelgeneAv야 회니 Pinterest () and LinkedIn ().
미소알바 Forward-LookingStatements Av야
This press release contains forward-looking statements, which are generally statements that are not historical facts. Forward-looking statements can be identified by the words “expects,” “anticipates,” “believes,” “intends,” “estimates,” “plans,” “will,” “outlook” and similar expressions. Forward-looking statements are based on 텀블러야동검색 Thiscurrent plans, estimates, assumptions and projections, and speak only as of the date they are made. We undertake no obligation to update any forward-looking statement in light of new information or future events, except as otherwise required by law. Forward-looking statements involve inherent risks and uncertainties, most of which are difficult to predict and are generally beyond our control. Actual results or outcomes may differ materially from those implied by the forward-looking statements as a result of the impact of a number of factors, many of which are discussed in porn Thisdetail in Celgene Corporation’s Annual Report Av야 디케이0810 on Form 10-K and other reports filed with the Securities and Exchange Commission.
View source version on businesswire.com:Korea Newswire distributes your news 섹스스토리 Viewevery Av야 비슷한약 media channels through 섹스스토리 ViewAv야 밤토끼넷 industry’s largest Av야 마시는 press release 미니툰 Viewnetwork
|전화번호 :||영업시간 :|
|홈페이지 :||위치정보 :|
등록된 댓글이 없습니다.